A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease

NCT ID: NCT05193201

Last Updated: 2022-01-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-16
• Study Completion Date: 2022-12-31

Brief Summary

The purpose of this study is to explore the multiple-dose regimen of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

Detailed Description

This is a multi-center, open label, phase Ib clinical study. The effectiveness of the multiple-dose regimen of recombinant human thrombopoietin injection in the treatment of thrombocytopenia in patients with chronic liver disease is mainly verified by evaluating the proportion of responders with platelet count in the first 8 days after treatment. Cohort 1 (n=18) : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L. Cohort 2 (n=36) : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.

Conditions

Liver Disease Chronic; Thrombocytopenia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1 : 50*10^9/L ≤ Baseline of PLT < 75*10^9/L

The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

Group Type: EXPERIMENTAL

recombinant human thrombopoietin injection

Intervention Type: DRUG

recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days

Cohort 2 : 30*10^9/L ≤ Baseline of PLT < 50*10^9/L.

The multiple-dose regimen (15000 U subcutaneous injection once a day for 7 days) of recombinant human thrombopoietin (rhTPO) injection for the treatment of thrombocytopenia in patients with chronic liver disease.

Group Type: EXPERIMENTAL

recombinant human thrombopoietin injection

Intervention Type: DRUG

recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days

Interventions

recombinant human thrombopoietin injection

recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days

Intervention Type: DRUG

Other Intervention Names

rhTPO

Eligibility Criteria

Inclusion Criteria

• Gender: There is no limit to men and women.
• 18 years old to 75 years old.
• Liver cirrhosis diagnosed by biopsy/imaging due to chronic liver disease, and Child-Pugh classification is A and B. Patients with liver cirrhosis diagnosed by transient elastography technology can also be included in the group.
• Baseline platelet level: 30×10^9/L≤platelet count<75×10^9/L.
• Liver function ALT and aspartate aminotransferase (AST)≤5×ULN, total bilirubin≤1.5×ULN, blood creatinine≤1.5×ULN.
• Able to understand and be willing to comply with the requirements of the clinical trial protocol, and voluntarily sign a written informed consent form.

Exclusion Criteria

• Those who are known to be allergic to any component of this product.
• Patients with liver cirrhosis caused by drug-induced liver damage.
• Those with a history of splenectomy or liver transplantation.
• Previously or currently suffering from serious diseases of any organ or system other than the liver, including cardiovascular disease, blood system disease, and nervous system disease patients, as well as any other diseases judged by the investigator to be unsuitable for participating in this trial.
• Currently suffering from malignant tumors, including solid tumors and hematological malignancies.
• Those who are clearly diagnosed as liver failure.
• Liver cirrhosis with serious complications, including: hepatic encephalopathy, refractory ascites, upper gastrointestinal bleeding, etc.;.
• People who have previously or are currently suffering from any disease that may lead to reduced platelet count and/or abnormal platelet function except for chronic liver disease and cirrhosis, including aplastic anemia, myelodysplastic syndrome, myelofibrosis, etc.
• Those who have undergone intrahepatic portosystemic shunt via jugular vein in the past.
• Doppler ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI) and other imaging examinations that indicate the presence of portal vein thrombosis within 28 days before administration.
• Use heparin, warfarin, non-steroidal anti-inflammatory drugs, aspirin, verapamil, and ticlopidine or glycoprotein IIb/IIIa antagonist (such as tirofiban) within 7 days before administration treat.
• Interferon has been used within 14 days before administration.
• Have received platelet transfusion or used platelet-containing blood products within 14 days before administration, except for transfusion of concentrated red blood cells.
• Those who have received any platelet-increasing therapy within 28 days before administration (the platelet-increasing function of Li Kejun, caffeic acid tablets and/or certain Chinese medicines or Chinese patent medicines that have the function of increasing platelet function can be accepted within 14 days), including but not Limited to rhTPO.
• No more than 28 days after the cessation of other research drug treatments or device research treatments carried out before the administration.
• There are currently patients with WHO ≥ Grade 2 active bleeding, or those with active bleeding in the past 2 weeks.
• Known human immunodeficiency virus positive or Treponema pallidum antibody positive.
• Combined with severe infections that cannot be effectively controlled (except for chronic hepatitis B and chronic hepatitis C).
• The subjects did not agree to take effective contraceptive measures during the trial period. The female subjects had a positive blood pregnancy test during the screening period; women who were pregnant or breastfeeding or had pregnancy plans within 3 months.
• Subjects' understanding, communication and cooperation are not enough to guarantee that the research will be carried out in accordance with the protocol.
• The researcher believes that the subjects are not suitable to participate in this study due to other reasons.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yimin Cui, PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University First Hospital

Xiaoyuan Lin, Master

Role: PRINCIPAL_INVESTIGATOR

Peking University First Hospital

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Gang Tong, MD

Role: CONTACT

tonggang@3sbio.com

021-60970099

Facility Contacts

Yimin Cui, PhD

Role: primary

cuiymzy@126.com

010-66110802

Xiaoyuan Lin, Master

Role: backup

xiaoyuanxu6@163.com

010-83575787

Other Identifiers

3SBio-TPO-106-Ib-01

Identifier Type: -

Identifier Source: org_study_id